Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Mario Alberto Accardi Sells 15,000 Shares of Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Mario Alberto Accardi sold 15,000 shares of the business’s stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00. Following the transaction, the insider now owns 216,485 shares of the company’s stock, valued at approximately $3,030,790. The trade was a 6.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Centessa Pharmaceuticals Stock Down 5.4%

Shares of NASDAQ:CNTA opened at $13.43 on Thursday. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $8.46 and a 52-week high of $19.09. The stock’s fifty day simple moving average is $12.79 and its 200-day simple moving average is $14.78. The company has a market capitalization of $1.79 billion, a P/E ratio of -7.42 and a beta of 1.48.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.15. As a group, equities research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the subject of a number of research reports. Needham & Company LLC initiated coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a “buy” rating and a $35.00 price target for the company. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued a “buy” rating and a $30.00 price target for the company. Morgan Stanley reissued an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price target for the company. Finally, Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an “overweight” rating and a $38.00 price target for the company. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.89.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CNTA. JPMorgan Chase & Co. lifted its position in shares of Centessa Pharmaceuticals by 40.1% in the fourth quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company’s stock valued at $3,189,000 after acquiring an additional 54,482 shares in the last quarter. Wellington Management Group LLP lifted its position in Centessa Pharmaceuticals by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock worth $1,928,000 after buying an additional 14,494 shares during the period. Franklin Resources Inc. increased its stake in Centessa Pharmaceuticals by 0.3% during the fourth quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock worth $38,668,000 after acquiring an additional 6,000 shares during the last quarter. Geode Capital Management LLC increased its stake in Centessa Pharmaceuticals by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after acquiring an additional 660 shares during the last quarter. Finally, Trexquant Investment LP increased its stake in Centessa Pharmaceuticals by 52.8% during the fourth quarter. Trexquant Investment LP now owns 261,184 shares of the company’s stock worth $4,375,000 after acquiring an additional 90,233 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.